著者

岡田 章 松本 結希 山越 達也 西川 誠 福島 恵造 杉岡 信幸

出版者

一般社団法人日本医療薬学会

雑誌

医療薬学 (ISSN:1346342X)

巻号頁・発行日

vol.40, no.12, pp.716-725, 2014-12-10 (Released:2015-12-10)

参考文献数

25

被引用文献数

1

---

Recently, use of inhaled corticosteroid anti-asthmatic drugs has been increasing due to the increase of bronchial asthma patients. However, there are some side effects of inhaled corticosteroid, such as hoarseness, which can affect a patient's quality of life (QOL). Therefore, to contribute to the proper and individual use of these anti-asthmatic drugs, we conducted a statistical analysis to determine the cause of hoarseness by collecting information to find a relationship between the rate of patients suffering from hoarseness, their personal backgrounds and each inhaled corticosteroid.In our present study, the rate of hoarseness onset in smokers was 4.15 times higher than that of non-smokers. On the other hand, fluticasone propionate (FP) is the component of inhaled anti-asthmatic drugs, which has the largest average particle size. Rate of hoarseness onset of inhaled FP was higher than any other component of inhaled corticosteroids. However, in inhaled anti-asthmatic drugs having FP as the main corticosteroid component, difference of the onset of hoarseness was observed between five nozzle types of devices. This result suggested that the cause of this difference was derived from the individual shape of the device's nozzle.In this study, it was revealed that the difference in nozzle types of devices and the particle size of drug components affect mainly the occurrence frequency of hoarseness. These results provide helpful information about appropriate use of inhaled anti-asthmatic drugs including effective patient education for self-administration.

著者

小倉 史愛 木村 丈司 宇田 篤史 戸田 飛鳥 赤澤 由子 山本 和宏 五百蔵 武士 西岡 達也 久米 学 槇本 博雄 平井 みどり

出版者

一般社団法人日本医療薬学会

雑誌

医療薬学 (ISSN:1346342X)

巻号頁・発行日

vol.42, no.2, pp.78-86, 2016-02-10 (Released:2017-02-15)

参考文献数

34

被引用文献数

2 5

---

Polypharmacy, the co-prescribing of nonessential drugs and inappropriate prescriptions, is a worldwide issue and is a factor affecting the increase in adverse drug reactions, drug-drug and drug-disease state interactions, and the growth in medical spending. In this study, we evaluated the current status of polypharmacy in elderly patients at Kobe University Hospital and the efficacy for screening and intervention against potentially inappropriate medications (PIMs) with the screening tool of older persons' potentially inappropriate prescriptions (STOPP) criteria formulated by a pharmacist. Of 301 study patients, 81 (26.9%) patients with PIMs were identified using the STOPP criteria, and these patients had a significantly higher number of prescribed drugs than other patients. Moreover, there was a correlation between the number of prescribed drugs and the percentage of patients identified using the STOPP criteria. The STOPP criteria identified 125 cases to be PIMs, and the prescriptions were changed for 35 (28%) of them. In 125 cases of PIMs, 61 cases had been strongly recommended prescription changes by pharmacists, of which 32 cases (52.5%) had been changed. Several prescription changes were often associated with the administration of nonsteroidal anti-inflammatory drugs. Based on our findings, we suggest that the STOPP criteria are useful for screening PIMs in Japanese patients and are a helpful tool for managing polypharmacy. The benefits of this approach for pharmacists should be multilaterally evaluated by the assessment of patients and medical economic outcomes in the future.

著者

渡邊 美智留 三田 恭平 中村 春世 田中 恒明 三原 潔 小野 秀樹

出版者

一般社団法人日本医療薬学会

雑誌

医療薬学 (ISSN:1346342X)

巻号頁・発行日

vol.40, no.12, pp.726-733, 2014-12-10 (Released:2015-12-10)

参考文献数

9

---

Pregabalin, a useful drug for neuropathic pain, has a high incidence of dizziness and somnolence as side effects. In the present study, the incidence of both side effects and the risk factors were retrospectively investigated in hospitalized patients who were administered pregabalin after their admission. In 65 patients (median 68 years old), 34 cancer patients and 18 opioid users were included. Items studied were cancer/non-cancer, opioid user/non-user, fall/nonfall, age, sex, weight, daily dose of opioids, the number of the drugs that may cause dizziness and somnolence, daily dose of pregabalin, and the ratio of creatinine clearance to daily dose of pregabalin. Fourteen (21.5%) and 21 (23.3%) patients developed dizziness and somnolence, respectively, and 4 (6.1%) patients developed fall. In the case of opioid combination, 7 (38.9%) and 10 (55.6%) patients developed dizziness and somnolence, respectively. A logistic-regression analysis showed that opioid use is a significant augmenting risk factor for dizziness (P = 0.026) and somnolence (P = 0.016) of pregabalin. The ratios of daily dose of pregabalin to creatinine clearance did not show any relation to the incidence of dizziness and somnolence; both side effects were observed in some patients whose renal functions were normal. It is suggested that attention is necessary to the incidence of dizziness and somnolence regardless of renal function, and that particular attention is required when opioids, which have similar side effects, are combined with pregabalin.

著者

大野 能之 樋坂 章博 岩本 卓也 木村 丈司 百 賢二 米澤 淳 伊藤 清美

出版者

一般社団法人日本医療薬学会

雑誌

医療薬学 (ISSN:1346342X)

巻号頁・発行日

vol.44, no.11, pp.537-545, 2018-11-10 (Released:2019-11-10)

参考文献数

11

---

The first academic subcommittee of the Japanese Society of Pharmaceutical Health Care and Sciences has a plan to create a guide on how to manage drug interactions in clinical settings. This review describes the information that forms the basis of the guide. This article, part (1), reports the results of a questionnaire on the content of the guide and also describes how to evaluate and manage drug interactions in clinical settings. The contents of the ʻDrug Interaction Guideline for Drug Development and Labeling Recommendationsʼ, the new Japanese guideline, are also described. It is important also in clinical practice to appropriately evaluate and manage drug interactions based on a sufficient understanding of the new guideline and related information.

著者

齊藤 幹央 宇野 勝次 本田 吉穂 渡辺 徹

出版者

一般社団法人日本医療薬学会

雑誌

医療薬学 (ISSN:1346342X)

巻号頁・発行日

vol.27, no.1, pp.29-32, 2001-02-10 (Released:2011-03-04)

参考文献数

21

被引用文献数

4 6

---

The clinical efficacy of therapy for intractable hiccups using Shitei-to, a folk medicines, was evaluated in 21 patients. Clinical effectiveness was observed in 11 cases, thus resulting in an efficacy rate of 52.4%.Particularly, the hiccups were relieved within two days by the treatment of only Shitei-to in 6 cases, and by the administration of Shitei-to in 2 cases that had been unsuccessfully treated by other drugs for hiccups. In addition, the efficacy rate was 66.7% for centric hiccups and 16.7% for peripheral hiccups. Accordingly, the clinical efficacy of Shitei-to was observed to be significantly higher for centric hiccups than for peripheral hiccups (p< 0.05 Wilcoxon ranksum test).Our findings showed Shitei-to to be very effective for treating patients with intractable hiccups. Furthermore, the clinical efficacy of this herbal medicine was higher for centric hiccups caused by cerebropathy than for peripheral hiccups caused by internal disease.

著者

今井 達男 岡部 信彦

出版者

一般社団法人日本医療薬学会

雑誌

医療薬学 (ISSN:1346342X)

巻号頁・発行日

vol.41, no.12, pp.907-915, 2015-12-10 (Released:2016-12-10)

参考文献数

23

被引用文献数

1

---

The infectiousness of diseases such as: the measles, rubella, the mumps, and the chicken pox is quite strong. When people lack antibodies to these diseases, the chance for infection increases. On a university campus, a person without such antibodies can help spread such diseases. However, as vaccines are available for these diseases and people are vaccinated, the chance for infection and the spreading of these diseases will diminish. At our university, Tokyo University of Pharmacy and Life Sciences, at the start of the recent academic year, an antibody survey was taken of 2,647 students to see which students had lower levels of antibodies to help fight the spread of the aforementioned diseases. Our findings showed antibody-positive rates of 49.0% for the measles, 70.8% for rubella, 75.7% for the mumps, and 92.4% for the chicken pox. With the rate for the chicken pox being the only one meeting an acceptable standard (Fine) in terms of community immunity. On the other hand, although the vaccination rates for the measles and rubella were high, they did not meet an acceptable standard for community immunity (Fine). When the community immunity level is low, the risk of infection is increased and this could lead to an outbreak on campus and affect more than just individuals. In the future, we will encourage students to be fully vaccinated before entering school or soon after doing so in order to protect against such an outbreak from occurring.

著者

中村 安孝 大島 幹弘 小菅 和仁 山田 浩 松山 耐至

出版者

一般社団法人日本医療薬学会

雑誌

医療薬学 (ISSN:1346342X)

巻号頁・発行日

vol.38, no.4, pp.246-250, 2012-04-10 (Released:2013-04-10)

参考文献数

12

---

Previously, warfarin potassium (WF) was only marketed in tablet form. When the dose needed to be prepared in a form other than tablets, it was necessary to either grind or cut the tablets. When grinding such tablets, some degree of drug loss occurred due to adherence to the grinders, mortar and pestles, and power folders. These issues were finally solved by the sale of fine-grain WF products. However, it was thought that the prothorombin time-international normalized ratio (PT-INR) might be increased in patients who changed from ground tablets to the administration of fine-grain WF. Therefore, we investigated the PT-INR of such cases while also comparing the findings in cases of patients continuously administered with WF in tablet form. The average PT-INR in patients that changed from the ground form to the administration of fine-grain WF was 1.81 (before the change) and 1.94 (after), thus showing a slight increase, but not one that was statistically significant. When the fluctuation range of PT-INR was compared with patients continuously taking WF tablets, the fluctuation ranges of PT-INR were 0.13 and 0.067, respectively, and no significant difference was observed. As a result, there is a possibility that the change to fine-grain WF may cause an increase in PT-INR, but such increase was restricted. In this study, an increase in PT-INR did not have any effect on the medical examination.

著者

植沢 芳広 内田 明宏 小山 茜 宇田川 三男 武田 直子 富澤 崇

出版者

一般社団法人日本医療薬学会

雑誌

医療薬学 (ISSN:1346342X)

巻号頁・発行日

vol.40, no.4, pp.215-221, 2014-04-10 (Released:2015-04-10)

参考文献数

7

被引用文献数

3 3

---

Patients' waiting times in a community pharmacy closely correlate with prescription dispensing times. Therefore, to decrease patients' stress and present an index in dispensing operations, various factors affecting prescription dispensing were analyzed, and a time-prediction model was constructed. The time from when a prescription was accepted (ie, handed in by a patient) to its checking, as well as time-factors affecting dispensing and checking, were measured at Kitayurakucho Pharmacy. Additional aspects were taken into account, such as: acceptance time, whether questions needed to be asked of the prescribing physician, medicine-counting, number of pharmacists present, and number of patients in the waiting area. Thereafter, a statistical prediction model for waiting time was constructed. It was found that drug counting and congestion level significantly related to waiting time. A multivariate regression model with two such parameters indicated a highly accurate prediction level. It is expected that prediction of the waiting time with this model will be useful for alleviation of the patients' stress.

著者

佐々木 誠 佐野 雅俊 田中 靖子 山本 育由

出版者

一般社団法人日本医療薬学会

雑誌

医療薬学 (ISSN:1346342X)

巻号頁・発行日

vol.32, no.5, pp.420-423, 2006-05-10 (Released:2007-11-09)

参考文献数

8

被引用文献数

5 3

---

Recently, at very low doses, carvedilol has improved the treatment of chronic heart failure. In Tenri Hospital, prescriptions for low dose carvedilol had been prepared by grinding a 10 mg tablet, adding lactose to it, and packaging the resulting powder. However, the drug loss in these processes had been causing problems in treating chronic heart failure. The present study examines the extent of drug loss in the grinding, sifting, and automatic packaging processes and the causes.The overall drug loss rate, as calculated by measuring the weight of the powder in the finished package, was 24.8±12.8, 33.9±13.2, and 28.0±9.3% for the 1.25, 2.5, and 5 mg packages, respectively, a considerable loss. The greatest loss was found to occur in the automatic packaging process. The drug loss rates for carvedilol itself were 56.4±8.1, 50.2±10.2, and 36.9±7.5% for the 1.25, 2.5, and 5 mg packages, respectively. The loss of carvedilol was greater for the 1.25 and 2.5 mg packages than the 5 mg package (p<0.05).These results suggest that the grinding of a 10 mg tablet gives rise to inaccurate dosing. Thus, low dose tablets available on the market should be used preferentially when low dosages of carvedilol are prescribed to patients with chronic heart failure.

著者

池谷 怜 此村 恵子

出版者

一般社団法人日本医療薬学会

雑誌

医療薬学 (ISSN:1346342X)

巻号頁・発行日

vol.47, no.9, pp.453-463, 2021-09-10 (Released:2022-09-10)

参考文献数

9

被引用文献数

1

---

This retrospective cohort study aimed to evaluate the utility of the family pharmacist system using administrative claims data. The eligible cohort was detected from the JMDC claims database; it was divided into two groups-those using the system (users) and those not using the system but receiving general pharmaceutical management (non-users) in health insurance pharmacies. The calculation of chouhukutouyaku-sougosayoutou-boushi-kasan-which consisted of the calculation other than the adjustment of leftover drugs and the calculation related to the adjustment of leftover drugs-was considered an indicator of the system’s utility. This indicator was compared between the two groups from April 2018 to March 2020, and a generalized linear model (link, identity; distribution, binomial) was developed to estimate the adjusted absolute risk differences (ARDs) and 95% confidence intervals (CIs). A total of 162,340 patients were included in the eligible cohort (users [n = 1,214]; non-users [n = 161,126]). Chouhukutouyaku-sougosayoutou-boushi-kasan was examined among 177 participants (14.6%) of users and 9,052 (5.6%) of non-users (adjusted ARD, 5.1; 95% CI, 3.2 to 7.1). Furthermore, the adjusted ARD was 3.1 (95% CI, 1.6 to 4.7) and 2.4 (95% CI, 1.0 to 3.7), for the calculation other than the adjustment of leftover drugs and the calculation related to the adjustment of leftover drugs, respectively. The current study reported that the family pharmacist system was related to the increase in the calculation of chouhukutouyaku-sougosayoutou-boushi-kasan. Therefore, it is suggested that the system was useful for facilitating pharmaceutical management in health insurance pharmacies.

著者

山下 修司 野口 義紘 窪田 傑文 井口 和弘 青木 慎也 多根井 重晴 中村 光浩 寺町 ひとみ 杉山 正

出版者

一般社団法人日本医療薬学会

雑誌

医療薬学 (ISSN:1346342X)

巻号頁・発行日

vol.41, no.3, pp.198-204, 2015-03-10 (Released:2016-03-10)

参考文献数

15

被引用文献数

7 7

---

Light emitting diodes (LEDs) are widely used in lighting applications. In this study, we examined the differences in the degree of the color change of various medicines between LED lighting and fluorescent lighting. The degree of the color change of the medicines was evaluated subjectively, by the observation of the evaluator, as well as objectively, using a colorimeter. Noticeable color changes were observed in the Lasix® 20-mg Tablet(Tab), Fluitran® 2-mg Tab, and Phenobal® powder after exposure to either LED lighting or fluorescent lighting. Interestingly, the color change of the Lasix® 20-mg Tab was smaller for the LED lighting than for the fluorescent lighting.

著者

大野 能之

出版者

一般社団法人日本医療薬学会

雑誌

医療薬学 (ISSN:1346342X)

巻号頁・発行日

vol.39, no.5, pp.257-270, 2013-05-10 (Released:2014-05-10)

参考文献数

33

被引用文献数

1

---

Renal dysfunction and drug-drug interactions (DDIs) can affect the clearance of various drugs from the body; however, these effects are difficult to sufficiently evaluate in clinical studies. This article outlines our recent approaches to improve the method of evaluating and providing the drug information on the effects of renal dysfunction and DDIs. These approaches aim to optimize the drug regimens of patients with renal dysfunction and to improve the management of DDIs. The renal excretion ratio (RR) is required to predict alterations in drug clearance in patients with renal dysfunction. However, the estimation of RR requires pharmacokinetic information that is not always provided in the Japanese drug package inserts or interview forms.A systematic approach to predict changes in drug clearance due to DDIs of the cytochrome p450 (CYP) is described. Uniquely, this method uses a small number of parameters, which are only obtained by in vivo DDI studies, i.e., the contribution ratio of CYPs to oral clearance of substrates (CR), the inhibition ratio of inhibitors (IR) or the increase in clearance by induction (IC). Changes in oral clearance for any combination of drugs can be predicted once these parameters have been calculated for each drug. These predictions were used to construct a pharmacokinetic interaction significance classification system (PISCS) to evaluate the clinical risk of DDIs in daily therapy.

著者

宮津 大輔 立石 裕樹 與田 賢作 松浦 徹 山下 大貴 安部 由起子 後藤 貴央 秋吉 正貴 田中 博和 平川 雅章

出版者

一般社団法人日本医療薬学会

雑誌

医療薬学 (ISSN:1346342X)

巻号頁・発行日

vol.47, no.7, pp.345-357, 2021-07-10 (Released:2022-07-10)

参考文献数

23

---

In January 2020, Fukuoka Tokushukai Hospital started Protocol Based Pharmacotherapy Management (PBPM), which allows pharmacists to order regular blood and urine tests for drugs that are recommended in the package insert, with the permission of the physician. The purpose of this initiative is to improve the quality of drug therapy for patients through the intervention of pharmacists, to reduce the burden on physicians, and to provide a solution to the three problems of drug therapy at our hospital. As a result, 204 PBPMs (203 blood tests and 1 urine test) were performed for a period of 8 months after the start of drug therapy. Most of them were additions to existing physician orders. All suggestions to the physician for tests were accepted, and 95% (96/101) of these were ordered by the pharmacist. In 37.3% (28/75) of the cases, the medication was changed after the test results.In addition, the "compliance rate of vancomycin (VCM) trough concentration measurement," "compliance rate of hepatitis B virus DNA (HBV-DNA) monitoring in oral chemotherapy alone," and "compliance rate of serum P concentration measurement during Continuous hemodiafiltration (CHDF)" increased after the start of PBPM compared with before (81.3% vs 91.7%, 82.6% vs 93.9%, and 65% vs 100%, respectively). We suggest that our PBPM is a useful tool for pharmacists to proactively promote appropriate drug therapy.

著者

今村 知世 加藤 有紀子 下方 智也 安藤 雄一 谷川原 祐介

出版者

一般社団法人日本医療薬学会

雑誌

医療薬学 (ISSN:1346342X)

巻号頁・発行日

vol.41, no.11, pp.759-767, 2015-11-10 (Released:2016-11-10)

参考文献数

21

被引用文献数

3

---

The renal clearance of carboplatin, which is a second-generation platinum compound, is correlated with the glomerular filtration rate (GFR). As the area under the concentration-time curve (AUC) of free carboplatin is related with efficacy and toxicity following carboplatin administration, carboplatin dosing is defined as a target AUC and generally calculated by the Calvert formula according to the patient's GFR. We conducted a survey on the usage of the Calvert formula to clarify the current situation in Japan. As a result, the value of creatinine clearance (CLcr), which is higher than GFR due to the tubular secretion of creatinine, has been used as a substitute for GFR for the Calvert formula without appropriate correction in 71 of 109 institutions, where CLcr estimated by a Cockcroft-Gault equation and/or obtained by 24-h urinary collection are used. On the other hand, body surface area-indexed values of renal function have been directly used without conversion to individual values in 42 of 71 institutions, where GFR estimated by a Japanese equation and/or CLcr estimated by a Jelliffe equation are used. It was found that the desired dosing of carboplatin has not been administered to patients in a number of institutions. Back to the original concept of the Calvert formula, it is reasonable to use a GFR estimated by the Japanese equation and converted to an individual value. In addition, we need to assess tolerability following carboplatin administration and discuss the appropriateness of the starting dose for each patient without being overly reliant on the dose obtained by the Calvert formula.

著者

武隈 洋 高地 里佳 石坂 悠 佐藤 夕紀 鷲見 正人 菅原 満

出版者

一般社団法人日本医療薬学会

雑誌

医療薬学 (ISSN:1346342X)

巻号頁・発行日

vol.40, no.3, pp.135-146, 2014-03-10 (Released:2015-03-10)

参考文献数

20

被引用文献数

3

---

This study determined the effects of long-term storage under various conditions after opening press through package (PTP) sheets on the stability of each tablet formula of statin for treatment of dyslipidemia and clarified the difference in stability between brand-name drugs and generic drugs.It was demonstrated that opened Crestor® tablets were stable for one year under the conditions of diffused light at room temperature and shielded light at room temperature. Although the content of rosuvastatin in ground Crestor® tablets was greatly decreased after only 1 month under the condition of diffused light, it was stable for at least 3 months under shielded light, indicating that shielded light is necessary for storage of ground Crestor® tablets. Of the four tablet formulae of simvastatin tested, only Lipola®M was within the stability standards after storage for 6 months under all conditions. The other tablet formulae of simvastatin showed changes in hardness or elution pattern even under the condition of shielded light at room temperature, indicating that care is needed in preparing one-dose packages of these formulae. Four tablet formulae of pravastatin used in this study were stable for 6 months under shielded light at room temperature. It was also found that three of the five formulae with decreasing elution velocity contained crospovidone and that the other formulae contained no crospovidone. This decrease in elution velocity appears to be due to reduction in porosity of the tablet caused by high humidity.

著者

赤木 祐貴 荒井 碧 下村 斉 山本 康次郎 青山 隆夫

出版者

一般社団法人日本医療薬学会

雑誌

医療薬学 (ISSN:1346342X)

巻号頁・発行日

vol.41, no.6, pp.404-414, 2015-06-10 (Released:2016-06-10)

参考文献数

37

被引用文献数

1 1

---

Low-dose aspirin inhibits cyclooxygenase-1 (COX-1) on platelets irreversibly, suppressing platelet aggregation.Nonsteroidal anti-inflammatory drugs (NSAIDs) also inhibit COX-1 reversibly by forming a salt bridge. However, there is little information on the antiplatelet effects of the chronic use of NSAIDs (other than aspirin). We performed pharmacokinetics/pharmacodynamics (PK/PD) analysis using in vitro experimental data obtained when NSAIDs were added to human blank blood, and estimated the antiplatelet effects of continuous NSAID administration.Ibuprofen, diclofenac, indomethacin and loxoprofen were studied in a one-compartment model, and etodolac was studied in a two-compartment model. Platelet aggregation was measured after adding NSAIDs to platelet-rich plasma at a range of concentrations containing the maximum plasma concentrations of one clinical dose. We calculated the platelet-aggregation threshold index (PATI) as an index of aggregation activity, which was defined as the putative stimulus concentration giving 50% aggregation, and performed PD analysis according to the sigmoidal Emax model. Simulated time-PATI curves of NSAIDs were compared to that of low-dose aspirin.Simulated values of increase in PATI for the maximum plasma concentration of each NSAID were lower than 3.9 µg/mL, which is the same as that of low-dose aspirin. Increases in PATI around the trough concentration were nearly zero for all NSAIDs except ibuprofen, thus suggesting that the antiplatelet effects of continuous NSAID administration are weaker and less persistent than those of low-dose aspirin. The simulation results indicate that continuous NSAID administration is less effective at preventing thrombosis and embolism than low-dose aspirin, and postoperative NSAID treatment needs to be careful of the occurrence of bleeding.

著者

髙見 陽一郎 松岡 哲史 岡﨑 大祐 小川 壮寛 佐藤 展子 森 翔馬 酒井 将弘 中川 碧 島田 憲一 江川 孝

出版者

一般社団法人日本医療薬学会

雑誌

医療薬学 (ISSN:1346342X)

巻号頁・発行日

vol.42, no.7, pp.536-542, 2016-07-10 (Released:2017-07-10)

参考文献数

7

---

We previously reported that various amounts of hazardous drugs, cyclophosphamide and fluorouracil had contaminated both the inside and outside of their blister packs. However, contamination from the non-antineoplastic drug, dutasteride, which primarily has adverse reproductive effects on female healthcare workers in the clinical setting, pregnant women and their families, has not been elucidated. Here we show that dutasteride was detected on both the inside and outside of blister packs of Avolve® Capsules. The amount of dutasteride extracted from blister packs and softcapsules was measured by LC-MS/MS. In addition, dutasteride was also detected on the surface of the softcapsules. Dutasteride attached to the surface of a capsule can become attached to others by physical contact. Our data suggest that pregnant women and their families can be exposed to dutasteride attached to blister packs and the surface of capsules, and female healthcare workers in contact with Avolve® Capsules can also be exposed to dutasteride. It is necessary to take measures to prevent unintended exposure to females.

著者

下石 和樹 安楽 誠 庵原 大輔 平山 文俊 門脇 大介 陣上 祥子 丸山 徹 小田切 優樹

出版者

一般社団法人日本医療薬学会

雑誌

医療薬学 (ISSN:1346342X)

巻号頁・発行日

vol.44, no.2, pp.55-60, 2018-02-10 (Released:2019-02-10)

参考文献数

8

---

Because it is essential to restrict phosphorus intake in dialysis patients, we investigated the phosphorus content per daily standard dose for eight different types of Chinese medicine and 12 different supplements, all of which are typically used by dialysis patients. Phosphorous contents in the range of 3-12 mg were detected in all of the Chinese medicines. Although 11 of the 12 kinds of supplements contained phosphorous, the levels were less than those in the Chinese medicines. The highest phosphorus content among those supplements was found in glucosamine, with a phosphorous content of 6 mg per dose. The phosphorous contents of glucosamine samples obtained from five different companies were all different. Taking these findings together, the intake of phosphorus by dialysis patients heeds to be restricted and the phosphorus contents of Chinese medicines and supplements need to be taken into consideration, by evaluating the total phosphorus intake per day for such patients. Pharmacists should pay attention to maintaining the serum phosphorus level within a reference value by effectively using a phosphate binder if necessary.

著者

木村 丈司 岩本 卓也 大野 能之 樋坂 章博 百 賢二 米澤 淳 伊藤 清美

出版者

一般社団法人日本医療薬学会

雑誌

医療薬学 (ISSN:1346342X)

巻号頁・発行日

vol.44, no.11, pp.546-558, 2018-11-10 (Released:2019-11-10)

参考文献数

44

---

The first academic subcommittee of the Japanese Society of Pharmaceutical Health Care and Sciences has a plan to create a guide on how to manage drug interactions in clinical settings. This review describes the information that forms the basis of the guide. This article, part (2), summarizes the practice reports on managing drug interactions in clinical settings, their problems, and the proper concepts of drug interactions in patients with special background. Each pharmacist is expected to enhance the literacy of drug interactions and manage them adequately, which will lead to the improvement of clinical outcomes.

著者

上田 幹子 仁木 一順 上田 紘子 大石 美奈子 上島 悦子

出版者

一般社団法人日本医療薬学会

雑誌

医療薬学 (ISSN:1346342X)

巻号頁・発行日

vol.43, no.6, pp.320-327, 2017-06-10 (Released:2018-06-10)

参考文献数

8

被引用文献数

1

---

Maintaining the oral cavity function is important in the intake of medicine and for the effectiveness of the medication itself. However, little is known about the need for medical, dental and pharmacological cooperation. We conducted a questionnaire survey related to side effects in the oral cavity in community pharmacies (n = 272) near our hospital belonging to the Pharmaceutical Association. We obtained responses from 120 pharmacies (44.1%). We also obtained comments from some dentists and a dental hygienist about the responses. From the survey results, 75%, 60% and 40% of pharmacies have experienced consultation from patients concerning deglutition, dry mouth and gingival hyperplasia, respectively. It was revealed that a lot of pharmacies are consulted by patients about side effects in the oral cavity. Eighty percent of pharmacies alerted patients to bisphosphonate-related osteonecrosis of the jaw. However, many pharmacists were concerned that they didn't know the initial symptoms and when bisphosphonate should be discontinued prior to dental treatment. These dentists commented that it would be better for the patients to consult with a dentist whenever the patients felt discomfort in their oral cavity. In this study, it became clear that pharmacists and dentists need to exchange information and cooperate with each other. Community pharmacists can contribute to appropriate pharmacotherapy by preventing serious adverse effects using the knowledge of oral cavity medications, because patients first consult the pharmacists regarding the medication.